Medicus Pharma (MDCX) News Today $3.13 +0.10 (+3.30%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Medicus Pharma Enters Warrant Inducement AgreementJuly 14 at 9:23 AM | tipranks.comMedicus Pharma (MDCX) Projected to Post Quarterly Earnings on ThursdayJuly 9, 2025 | americanbankingnews.comMedicus Pharma submits Type C meeting request to FDA to advance skin cancer treatmentJuly 8, 2025 | proactiveinvestors.comMedicus Pharma expands pipeline with Antev acquisition - ICYMIJuly 5, 2025 | proactiveinvestors.comMedicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer TreatmentJuly 4, 2025 | seekingalpha.comMedicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK - Seeking AlphaJuly 2, 2025 | seekingalpha.comMedicus to acquire UK biotech Antev in share deal worth up to $65mJune 30, 2025 | proactiveinvestors.comMedicus Pharma appoints Andrew Smith as chief operating officerJune 24, 2025 | uk.investing.comMedicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studiesJune 23, 2025 | proactiveinvestors.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma to Present at Bio Convention and Expand Cancer Treatment PortfolioJune 12, 2025 | tipranks.comMedicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horsesJune 9, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug ...June 9, 2025 | gurufocus.comMedicus Pharma Submits FDA Plan for Novel Equine Cancer TreatmentJune 9, 2025 | tipranks.comMedicus Pharma appoints KPMG as new auditor, expands global clinical programsJune 6, 2025 | proactiveinvestors.comMedicus Pharma completes $7 million public offeringJune 4, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street ZenMay 31, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)May 30, 2025 | marketbeat.comMedicus Pharma unveils pricing of $7M public offeringMay 30, 2025 | proactiveinvestors.comMedicus Pharma prices $7 million share offeringMay 30, 2025 | msn.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock NewsMay 29, 2025 | gurufocus.comMedicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment TrialsMay 29, 2025 | tipranks.comMDCX Medicus Pharma Ltd.May 29, 2025 | seekingalpha.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.comMedicus Pharma's (MDCX) Buy Rating Reaffirmed at D. Boral CapitalMay 24, 2025 | marketbeat.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22, 2025 | proactiveinvestors.comMedicus Pharma gets UAE approval for Phase 2 study for skin cancer therapyMay 22, 2025 | proactiveinvestors.comMedicus Pharma Ltd. (NASDAQ:MDCX) Major Shareholder Velocity Fund Partners, Lp Sells 75,000 SharesMay 22, 2025 | insidertrades.comMedicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Misses Estimates By $0.19 EPSMay 14, 2025 | marketbeat.comD. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00May 14, 2025 | marketbeat.comMedicus Pharma LtdMay 14, 2025 | cnn.comMedicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial PortfolioMay 12, 2025 | benzinga.comMedicus Pharma to acquire Antev in strategic biotech dealApril 30, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Earns "Buy" Rating from D. Boral CapitalApril 30, 2025 | marketbeat.comMedicus Pharma signs letter of intent to buy British biotech companyApril 29, 2025 | bizjournals.comMedicus Pharma Ltd (MDCX)April 29, 2025 | investing.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange TransactionApril 28, 2025 | finance.yahoo.comMedicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentApril 28, 2025 | proactiveinvestors.comMedicus Pharma to Acquire Antev Ltd. in $75 Million DealApril 28, 2025 | tipranks.comMedicus Pharma (NASDAQ:MDCX) Receives "Buy" Rating from D. Boral CapitalApril 23, 2025 | marketbeat.comMedicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma TreatmentApril 21, 2025 | tipranks.comMedicus Pharma expands basal cell carcinoma study after encouraging early dataApril 21, 2025 | proactiveinvestors.comD. Boral Capital Initiates Coverage of Medicus Pharma (MDCX) with Buy RecommendationApril 14, 2025 | msn.comResearch Analysts Set Expectations for Medicus Pharma Q1 EarningsApril 12, 2025 | marketbeat.comMedicus Pharma Ltd. (MDCX)March 25, 2025 | finance.yahoo.comMedicus Pharma announces annual meeting dateMarch 22, 2025 | investing.comMedicus Pharma Secures $4.2 Million for Innovative Skin Treatment TrialsMarch 10, 2025 | tipranks.comMedicus Pharma CEO discusses latest skin cancer trial results - ICYMIMarch 8, 2025 | proactiveinvestors.com Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCX Media Mentions By Week MDCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDCX News Sentiment▼0.660.98▲Average Medical News Sentiment MDCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDCX Articles This Week▼52▲MDCX Articles Average Week Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Innate Pharma News Journey Medical News Nuvectis Pharma News Aclaris Therapeutics News Upexi News DiaMedica Therapeutics News Instil Bio News Alector News Compugen News Inhibikase Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDCX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDCX Stock Alerts